706 related articles for article (PubMed ID: 21500468)
1. [Tamoxifen and endometrial pathology].
Negoiţă M; Terinte C; Mihailovici MS
Rev Med Chir Soc Med Nat Iasi; 2010; 114(4):1114-7. PubMed ID: 21500468
[TBL] [Abstract][Full Text] [Related]
2. Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen.
Lee M; Piao J; Jeon MJ
Yonsei Med J; 2020 Apr; 61(4):317-322. PubMed ID: 32233174
[TBL] [Abstract][Full Text] [Related]
3. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound.
Gerber B; Krause A; Müller H; Reimer T; Külz T; Makovitzky J; Kundt G; Friese K
J Clin Oncol; 2000 Oct; 18(20):3464-70. PubMed ID: 11032586
[TBL] [Abstract][Full Text] [Related]
4. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer.
Deligdisch L; Kalir T; Cohen CJ; de Latour M; Le Bouedec G; Penault-Llorca F
Gynecol Oncol; 2000 Aug; 78(2):181-6. PubMed ID: 10926800
[TBL] [Abstract][Full Text] [Related]
5. The endometrium in breast cancer patients on tamoxifen.
Dallenbach-Hellweg G; Schmidt D; Hellberg P; Bourne T; Kreuzwieser E; Dören M; Rydh W; Rudenstam G; Granberg S
Arch Gynecol Obstet; 2000 Apr; 263(4):170-7. PubMed ID: 10834325
[TBL] [Abstract][Full Text] [Related]
6. Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings.
Hann LE; Giess CS; Bach AM; Tao Y; Baum HJ; Barakat RR
AJR Am J Roentgenol; 1997 Mar; 168(3):657-61. PubMed ID: 9057510
[TBL] [Abstract][Full Text] [Related]
7. Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients.
Cohen I; Perel E; Flex D; Tepper R; Altaras MM; Cordoba M; Beyth Y
J Clin Pathol; 1999 Apr; 52(4):278-82. PubMed ID: 10474520
[TBL] [Abstract][Full Text] [Related]
8. Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy.
McGonigle KF; Shaw SL; Vasilev SA; Odom-Maryon T; Roy S; Simpson JF
Am J Obstet Gynecol; 1998 Jun; 178(6):1145-50. PubMed ID: 9662294
[TBL] [Abstract][Full Text] [Related]
9. The value of transvaginal ultrasonography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients.
Markovitch O; Tepper R; Fishman A; Shapira J; Aviram R; Cohen I
Gynecol Oncol; 2004 Dec; 95(3):456-62. PubMed ID: 15581946
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer.
Dibi RP; Zettler CG; Pessini SA; Ayub AV; de Almeida SB; da Silveira GP
Menopause; 2009; 16(2):293-300. PubMed ID: 19034048
[TBL] [Abstract][Full Text] [Related]
11. Sonohysterography for evaluation of the endometrium in women treated with tamoxifen.
Hann LE; Gretz EM; Bach AM; Francis SM
AJR Am J Roentgenol; 2001 Aug; 177(2):337-42. PubMed ID: 11461858
[TBL] [Abstract][Full Text] [Related]
12. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen.
Fung MF; Reid A; Faught W; Le T; Chenier C; Verma S; Brydon E; Fung KF
Gynecol Oncol; 2003 Oct; 91(1):154-9. PubMed ID: 14529676
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of endometrium during tamoxifen therapy of breast cancer].
Obrebowska A; Sibila-Owczarska A; Sajdak S
Ginekol Pol; 2002 Nov; 73(11):1109-12. PubMed ID: 12722407
[TBL] [Abstract][Full Text] [Related]
14. Endometrial pathologies associated with postmenopausal tamoxifen treatment.
Cohen I
Gynecol Oncol; 2004 Aug; 94(2):256-66. PubMed ID: 15297160
[TBL] [Abstract][Full Text] [Related]
15. [Uterine pathology in women with breast cancer treated with tamoxifen].
Carcangiu ML
Pathologica; 1997 Jun; 89(3):223-33. PubMed ID: 9380417
[No Abstract] [Full Text] [Related]
16. Spectrum of tamoxifen associated endometrial pathology in breast cancer patients.
Qureshi A; Bukhari F; Pervez S
J Pak Med Assoc; 2009 Apr; 59(4):249-50. PubMed ID: 19402291
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies.
Jeon J; Kim SE; Lee DY; Choi D
Breast Cancer Res Treat; 2020 Jan; 179(1):125-130. PubMed ID: 31541382
[TBL] [Abstract][Full Text] [Related]
18. [Uterine abnormalities in non menopausal women who received tamoxifen for breast cancer adjuvant therapy].
d'Arailh AS; Michy T; Pioud R; Dravet F; Classe JM
Gynecol Obstet Fertil; 2007 Dec; 35(12):1215-9. PubMed ID: 18035581
[TBL] [Abstract][Full Text] [Related]
19. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
Cheng WF; Lin HH; Torng PL; Huang SC
Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
[TBL] [Abstract][Full Text] [Related]
20. [Expression of hormonal receptors (alpha-estrogen, beta-estrogen, progesteron), Ki-67 and P53 in endometrium of tamoxifen treated breast cancer patients].
Negoiţă M; Mihailovici MS
Rev Med Chir Soc Med Nat Iasi; 2011; 115(3):834-8. PubMed ID: 22046795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
